Novartis confirmed to Reuters that it stopped the ORION-17 trial, which was planned to have 40,000 patients and designed to show that Leqvio could prevent the first occurrence of major cardiovascular health problems in high-cholesterol patients. "After careful evaluation, we have decided not to move forward with ORION-17. We continue to have very high ambitions for Leqvio," the company told Reuters in a statement. Novartis said it would pursue a different global trial with 14,000 volunteers to show Leqvio’s potential in primary prevention in people at high risk of suffering a first cardiovascular event, Ludwig Burger and Kanjyik Ghosh of Reuters report. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVS:
- Novartis alpelisib granted FDA orphan designation
- Novartis’ Sandoz receives FDA approval for biosimilar Hyrimoz HCF
- Novartis terminates collaboration and license pact with Sangamo
- Novartis’ Tafinlar + Mekinist approved by FDA for pediatric patients
- Novartis’ Sandoz signs MOU to build new biologics production plant in Slovenia